Anil Tarachandani to present at ALS Drug Discovery Summit

We’re excited to share that Anil Tarachandani, our VP & Head of Translational Medicine, will be presenting at the upcoming ALS Drug Discovery Summit next week. Anil will discuss our ongoing research into the use of digital clinical biomarkers in Amyotrophic Lateral Sclerosis (ALS) clinical studies.

Digital biomarkers offer the potential for greater precision, reduced variability, and enhanced sensitivity to change—key advantages that could make early-phase trials, such as Proof of Concept and dose-ranging studies, more efficient and informative. By leveraging these tools, we aim to accelerate the development of effective treatments and help transform the therapeutic landscape for individuals living with ALS.